Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict who will suffer severe leptospirosis?

NCT ID NCT04034550

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study follows 200 hospitalized patients with suspected or confirmed leptospirosis, a bacterial infection spread by animals. Researchers will collect blood and urine samples and track patients for a year to gather data on the disease's symptoms, severity, and immune response. The goal is to better understand why some patients develop severe organ failure or die, which could help improve future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood and urine sampling and blood banking
What this could lead to
This could lead to a deeper understanding of leptospirosis, potentially improving how doctors predict and manage severe cases.
What could go wrong
This is an observational study, so it won't test a new treatment. It may not change clinical practice directly, and findings depend on the patient group studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 day and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * clinico-biological manifestations compatible with acute leptospirosis OR proven leptospirosis with serological testing or PCR * onset of symptoms within 21 days * participant benefits of health insurance Exclusion Criteria: * participant's refusal, or refusal from his relatives in case of major incapacity of the eligible participant precluding expression of his will (coma, stay in intensive care unit))

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leptospirosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leptospirosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leptospirosis

Contacts and locations

Locations

  • CHU de La Réunion site Nord

    Saint-Denis, Reunion, 97400, France

  • CHU de La Réunion site Sud (GHSR)

    Saint-Pierre, Reunion, 97410, France

  • Centre Hospitalier Ouest Réunion (CHOR)

    Saint-Paul, Reunion, 97460, France

  • Groupe Hospitalier Est Réunion (GHER)

    Saint-Benoît, Reunion, 97470, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.